about
Evaluation and modification of commercial dry powder inhalers for the aerosolization of a submicrometer excipient enhanced growth (EEG) formulationAerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performanceDrug-targeting methodologies with applications: A reviewThe effect of solvent treatment on the performance of various carriers in dry powder inhalations containing salbutamol sulphateDry powder inhalers for pulmonary drug delivery.Cyclodextrins in drug delivery.In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).Influence of fluoxetine on olanzapine pharmacokinetics.Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease.Lactose engineering for better performance in dry powder inhalers.Dry powder inhalation: past, present and future.Measuring surface roughness of pharmaceutical powders using vapor sorption methods.Effect of rise in simulated inspiratory flow rate and carrier particle size on powder emptying from dry powder inhalers.Effect of cholesterol on the properties of spray-dried lysozyme-loaded liposomal powders.Crystal engineering of lactose using electrospray technology: carrier for pulmonary drug delivery.Highly reproducible powder aerosolisation for lung delivery using powder-specific electromechanical vibration.Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.
P2860
Q28387314-2A627BE1-2D02-45BA-9A9A-E7E6C43E2F89Q28394991-E23F09BF-077D-487C-89C1-739A8B8A9B29Q28649786-0387EC79-70B9-4305-8AE9-D65F30CFF38AQ31136433-C72C192E-5DFB-4322-A346-BDD91F589FCBQ36316621-C4746037-F380-49B0-BF03-1B14EECBE857Q36316735-B8384899-6A26-4DE6-A4ED-1207318D8460Q36388505-08A6EE8A-44A2-431D-8E58-42D0A168E24CQ37361790-30E94492-8820-4687-8D8C-FAAC7B3D10C2Q37849777-953783EE-DFFF-43CC-97F8-856F726FD99DQ38169161-B3C06453-6B38-4A1B-B67A-A5C8359CF2B9Q38830375-E428DF6F-C85C-4290-B184-D8C54B97A160Q41810299-0C00EAFC-7FC3-42A0-9A1B-88159BCB4715Q41842008-2F6B6905-61D2-4541-B03C-404C13C2DC89Q41948576-69115AAC-2AFC-416D-8976-B8C5A6B1DBF9Q47766150-3A57E614-40B5-4CCA-B287-E146862AA8E0Q51317842-DE2266D1-CB4E-4BF2-B948-21994E04C7A4Q53072416-0B46259B-005D-4EA9-84C4-E35A4916F385
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Review of dry powder inhalers.
@ast
Review of dry powder inhalers.
@en
type
label
Review of dry powder inhalers.
@ast
Review of dry powder inhalers.
@en
prefLabel
Review of dry powder inhalers.
@ast
Review of dry powder inhalers.
@en
P2093
P1476
Review of dry powder inhalers.
@en
P2093
P356
10.1016/S0169-409X(97)00510-3
P407
P577
1997-06-01T00:00:00Z